Pionyr Immunotherapeutics Secures $8,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bfba97b2-fce9-4ffa-8c94-741f7a04802f - Date
1/5/2017 - Company Name
Pionyr Immunotherapeutics - Mailing Address
953 Indiana St. San Francisco, CA 94107 USA - Company Description
Pionyr develops drugs to perform exceptional fine-tuning of immune responses. This goal addresses a current and justified excitement about immunotherapy and introduces technology to rapidly identify and target novel arms of the immune response, within the tumor microenvironment (TME). - Website
http://www.precisionimmune.com - Transaction Type
Venture Equity - Transaction Amount
$8,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
OrbiMed - Venture Investor
SV Life Sciences - Venture Investor
Osage Partners - Venture Investor
Mission Bay Capital - Venture Investor
Investor - Venture Investor
Investor - Venture Investor
Investor - Venture Investor
Investor
